“Gedeon Richter House of Hope” opens its doors to support 300 women annually in Africa-Bamako
BUDAPEST, Hungary, May 6, 2025 /PRNewswire/ -- A center providing healthcare and educational support as well as shelter for vulnerable women has been built in Bamako, the capital of Mali, with financial assistance from Gedeon Richter. As one of the world's leading manufacturers of women's healthcare medications, Richter emphasizes the importance...
Global Survey from World Lupus Federation Finds Nearly Half of People with Lupus Report Kidney Involvement
New data highlights urgent need for improved education and diagnosis of lupus nephritis (lupus-related kidney disease), a serious complication of lupus WASHINGTON, May 6, 2025 /PRNewswire/ -- A global survey conducted by the World Lupus Federation reveals that 47% of people living with lupus report kidney involvement, which leads to a critical and under-recognized complication known...
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain. Oral Presentation Details Title: ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug...
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy (LMNA DCM) through to clinical proof-of-concept...
Asia Pacific Initiative on Reproduction (ASPIRE) 2025 Congress: Fatherhood role models a new focus in filling the gap between actual and desired family sizes
SINGAPORE, May 6, 2025 /PRNewswire/ -- Presenting fatherhood as cool, admirable and masculine is likely to headline a new fertility rebound initiative across the Asia Pacific region as birth rates continue to fall at alarming levels. Renowned reproductive endocrinologist Emeritus Professor Dominique de Ziegler said a "gender revolution" had seen increasing...
Fangzhou Launches Otsuka’s Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 6, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform, providing expanded treatment options for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic...
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announces that the latest 1-year results from its Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a recombinant human...
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 6, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP)...
INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness
Global antiviral R&D is slowing when the world can least afford it, new analysis shows CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition of its Antiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pipeline...
Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and development...
